Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience. Cabreira V, Dias L, Fernandes B, Aires A, et al. Acta Neurol Scand 2022;145:479-483.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cabreira V, Dias L, Fernandes B, Aires A, et al. Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience. Acta Neurol Scand 2022;145:479-483.
PMID: 34866181